Back to search results

Mobile Transcranial Magnetic Stimulation for Treatment-Resistant Depression

This study is testing a new way to deliver Transcranial Magnetic Stimulation (TMS) for people with depression that hasn't improved with other treatments (treatment-resistant major depression). TMS uses magnetic fields to stimulate nerve cells in the brain. Researchers are building a portable TMS unit in a van and will use it to treat up to 30 participants in three locations in South Carolina. The goal is to see if this mobile approach is practical, safe, and effective. To join, you must be an adult between 22 and 80 years old, have treatment-resistant depression, speak English, and be able to provide consent. The study will measure how many people's depression improves and how much their symptoms lessen after treatment. The study's current status is unclear.

Study design
This is a pilot study with 30 participants, testing a new way to deliver FDA-approved TMS in a mobile unit. It is an open-label study, meaning both participants and researchers will know what treatment is being given.
What's involved
Participants will receive 6 TMS sessions each day, over 2 hours, for 5 days, spread over one or two weeks. You will also need access to a computer for initial consent and a telescreen.
Compensation
Not stated in the trial record.
Follow-up
Researchers will measure improvement in depression symptoms and the percentage of responders from the start of the study to one week immediately after the treatment week.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06748209

Establishing Mobile Transcranial Magnetic Stimulation

Recruiting
PHASE4Ages 22–80InterventionalTreatment
Medical University of South Carolina
~30 participants
Updated 2026-05-06 on ClinicalTrials.gov
What's tested:Left prefrontal Transcranial Magnetic Stimulation (TMS)FDA cleared TMS for treating depression

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Percent of depression responders
Measured over From baseline to 1 week immediately after treatment week
+1 more outcome measured

Conditions

Treatment Resistant Major Depression

Explore related trials

AnxietyDepressionUnipolar Depression

Where it's being run

1 sites across 1 states
South Carolina1

Study leadership

  • Mark George, MD · PRINCIPAL_INVESTIGATOR · Medical University of South Carolina

Who to contact

Mark S George, MD
[email protected]
8438765142
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Adult (22-80 years old)
Have treatment-resistant depression as defined by the e-Mini, and the antidepressant treatment history form (ATHF short).
Be able to read and communicate in English.
Able to provide their own consent.
Access to a computer with videoconferencing ability for initial consent and telescreen.

Exclusion

Patients with unstable medical conditions that might make TMS unsafe. This includes current poorly controlled seizures.
Ferromagnetic metal in the head.
Pregnant.
Currently active substance abuse except tobacco.

What this trial measures

  • Percent of depression respondersFrom baseline to 1 week immediately after treatment week

    Number of patients with \>50% improvement in Phq-9 scores before and then after 5 days of treatment

  • Improvement in Depression SymptomsFrom baseline to 1 week immediately after treatment week

    Change in Phq-9 ratings from baseline to end of treatment